Large Molecule Biologics Delivery: Aligning Formulations, Doses, And Devices

Drug Delivery Leader Chief Editor Tom von Gunden was joined by expert panelists Rubi Burlage, Dominick DeGrazio, and John Higgins in a discussion of key formulation and delivery considerations during product development for large molecule, biologics-based therapies. Illustrating their points primarily in the context of delivery via prefilled syringes, autoinjectors, and combination products, the panel emphasized the centrality of the TPP (Target Product Profile) in guiding formulation, dosing, device selection, clinical bridging, and commercial scale-up.